VCYT

Veracyte, Inc.

25.25 USD

Last updated Dec 7, 19:15 UTC

Yesterday HIGH

$26.12

Yesterday LOW

$25.18

52w HIGH

$32.4

52w LOW

$19.52

EPS

0.07

PE

360.71

Next Earnings

Feb 21, 2024

Overview News Government Trades

Veracyte, Inc. stock is up 5.16% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 December’s closed higher than November. 50% of analysts rate it a buy.

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.

Stock Exchange

NASDAQ

Sector

Services

Industry

Healthcare

Headquarters

South San Francisco, United States Of America

Website

veracyte.com

Benzinga Newsdesk

Wed Aug 9, 2023

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $23

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $22 to $23.
richadhand@benzinga.com

Wed Aug 9, 2023

Needham Maintains Buy on Veracyte, Raises Price Target to $35

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $34 to $35.
Benzinga Newsdesk

Tue Aug 8, 2023

Veracyte Raises FY23 Revenue Guidance From $330M-$340M To $342M-$350M
saritha@benzinga.com

Tue Aug 8, 2023

Veracyte Q2 EPS $(0.12) Beats $(0.14) Estimate, Sales $90.32M Beat $74.66M Estimate

Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 7.69 percent increase over losses of $(0.13) per share from the same
Benzinga Insights

Tue Aug 8, 2023

Earnings Scheduled For August 8, 2023

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
Happy Mohamed

Tue Aug 1, 2023

Veracyte, Inc. Announces Study Published In JNCI Cancer Spectrum Demonstrates Real-World Utility Of Co's Decipher Prostate Genomic Classifier In Prostate Cancer Treatment

Clinical utility study findings based on analysis of the National Cancer Institute's SEER database Veracyte, Inc. (NASDAQ:VCYT) announced the publication of a large, real-world study reinforcing the Decipher
Happy Mohamed

Tue Jun 20, 2023

New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding Of Thyroid Nodules And Cancer

Findings presented at ENDO 2023 also confirm analytical validity of company's TERT promoter gene mutation testing for thyroid nodule patients Veracyte, Inc. (NASDAQ:VCYT) announced that new data presented at ENDO
Benzinga Newsdesk

Thu May 25, 2023

Veracyte Reports New Data To Be Shared At The 2023 American Society Of Clinical Oncology Annual Meeting

The company said new data to be shared demonstrate the ability of the company's Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights into prostate cancer. The
Happy Mohamed

Wed May 24, 2023

New Data Presented At ATS 2023 Reinforce Clinical Utility Of Veracyte's Genomic Tests In Interstitial Lung Disease And Lung Cancer

Veracyte, Inc. (NASDAQ:VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The
Benzinga Insights

Wed May 17, 2023

Looking Into Veracyte's Return On Capital Employed

Morgan Stanley

Fri Nov 10, 09:25

sell

confirm
Needham

Wed Nov 8, 17:01

buy

confirm